Tin tức & Cập nhật
Lọc theo Chuyên ngành:
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
17 Jul 2023
Meal replacement trumps food-based diet for improving CV risk factors in obese adults
In the secondary and exploratory analyses of the OPTIWIN trial, meal replacement (MR) outdid a food-based (FB) regimen in improving cardiometabolic risk in adults with obesity.
Meal replacement trumps food-based diet for improving CV risk factors in obese adults
17 Jul 2023
Danuglipron helps with glucose control, weight loss in T2D
The glucagon-like peptide 1 receptor (GLP-1R) agonist danuglipron appears to be beneficial in the treatment of patients with type 2 diabetes (T2D), yielding reductions in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight, without fasting restrictions, as shown in the results of a phase IIb study.
Danuglipron helps with glucose control, weight loss in T2D
15 Jul 2023
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.
